Human FVIII congenital deficient plasma with Anti-VIII inhibitor (Bethesda)
Frozen
Packaging options
| 6-PPD08C-INH | Vial | Minimum 50 mL |
Plasma from a single human donor with congenital Factor VIII deficiency with anti-VIII inhibitor.
Description of the Human FVIII congenital deficient plasma with Anti-VIII inhibitor (Bethesda)
Packaging in bottle. The minimum packaged volume is 50 mL. The price offer is based on the volume requested.
Advantages
Minimize test time.
Ready to use.
Informations
Factor VIII is a glycoprotein mainly synthesized by the liver. It circulates in the plasma in the form bound to VWF which protects it from rapid proteolytic degradation. It is activated by FXa or thrombin in FVIIIa which will complex with FIXa in the presence of phospholipids to activate FX in FXa.
A patient who is deficient in FVIII has hemophilia A.
product sheet